Medicine and Dentistry
COVID-19
100%
Ulcerative Colitis
75%
Inflammatory Bowel Disease
73%
Severe Acute Respiratory Syndrome Coronavirus 2
32%
Endoscopy
31%
Personalized Medicine
25%
Patient with Inflammatory Bowel Disease
25%
Patient Referral
25%
Butyrophilin
25%
T Cell
25%
Vedolizumab
25%
Case-Control Study
25%
Immunosuppressive Treatment
15%
Rescue Therapy
13%
Clinical Trial
11%
Primary Health Care
10%
Colectomy
10%
Biological Product
10%
Mucosa
10%
Leukocyte
10%
Spontaneous Remission
10%
Integrin
10%
Infection
8%
Tofacitinib
8%
Combination Therapy
6%
Social Distancing
6%
Coronavirinae
6%
Immunosuppressive Drug
6%
Hydrocortisone
5%
Anticoagulation
5%
Azathioprine
5%
Maintenance Therapy
5%
Nurse Consultant
5%
Infliximab
5%
Intestine Mucosa
5%
Side Effect
5%
Gut
5%
Tumor Necrosis Factor
5%
T Lymphocyte Receptor
5%
Cell Compartment
5%
Heteromer
5%
Monoclonal Antibody
5%
Phase III Trials
5%
Crohn's Disease
5%
Germ Cell
5%
Diseases
5%
Immunology and Microbiology
T Cell
60%
Innate Immune System
25%
Agonist
25%
Cytotoxic T-Cell
25%
Adaptive Immune System
25%
T Lymphocyte Antigen
25%
Skin Allergy
25%
Inflammatory Bowel Disease
25%
Cell Selection
25%
Programmed Death 1 Ligand 1
11%
Intraepithelial Lymphocyte
10%
Germ Cell
8%
Memory T Cell
8%
CD8
8%
Cell Maturation
5%
T Cell Receptor
5%
Crohn's Disease
5%
Integrin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
28%
Mercaptopurine
28%
Case-Control Study
25%
Ulcerative Colitis
25%
Biological Product
10%
SARS Coronavirus
9%
Monotherapy
8%
Tolerability
8%
Pandemic
6%
